Assessments of QOL on 53 prostatic cancer patients under LH-RH analogue treatment were evaluated using our own questionnaire. Three months after treatment, the improvement of ADL, appetite, physical symptoms, mental symptoms, sexual life and social life occurred in 24.3%, 51.5%, 44.7%, 29.7%, 7.5% and 35.4% of the patients, respectively. Twelve months after treatment, the improvement of them occurred in 30.9%, 48.4%, 31.7%, 33.7%, 8.3% and 34.4%, respectively. The quality of sexual life for the prostatic cancer patients treated with LH-RH analogue was worse than that of others. LH-RH analogue is effective on QOL in the treatment of prostatic cancer patients.